Albumin as a Delivery Carrier for Rheumatoid Arthritis
- *Corresponding Author:
- Lingdong Quan
Arthritis and Tissue Degeneration Program
Hospital for Special Surgery
535 East 70th Street
New York, NY 10021, USA
E-mail: [email protected]
Received Date: May 08, 2013; Accepted Date: June 13, 2013; Published Date: June 15, 2013
Citation: Ren K, Dusad A, Dong R, Quan L (2013) Albumin as a Delivery Carrier for Rheumatoid Arthritis. J Nanomed Nanotechol 4:176. doi:10.4172/2157-7439.1000176
Copyright: © 2013 Ren K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Rheumatoid Arthritis (RA) is a chronic autoimmune disease and considered to be one of the major public health problems worldwide. In the past decade numerous drug delivery systems have been developed to improve the treatment outcome of RA. A stable endogenous protein, albumin has been employed as a non-immunogenic delivery carrier and extensively researched in various disease therapies. To provide the prospective for future research, this review summarizes the application of albumin as drug or imaging agent carriers for RA and proposes potential future directions. There are three major types of albumin-based carrier systems for RA, including albumin drug conjugates, albumin particles and genetic infusion albumin. Their imaging or therapeutic effects have been proved in clinic or preclinical studies.